Adjuvant choice for FimA vaccine dictates B-cell epitope hierarchy, achieving 100% protection against lethal hvKP.
Background
Hypervirulent Klebsiella pneumoniae (hvKP) variants represent an urgent, multidrug-resistant threat against which no licensed vaccine currently exists. FimA, a fimbrial adhesin protein, is indispensable for KP mucosal colonization, making it a promising vaccine target. However, the specific immunodominant B-cell epitopes of FimA and how different adjuvants influence their hierarchy and protective efficacy in vaccines against hvKP have remained undefined. Understanding this interaction is critical for developing effective vaccine strategies against this formidable pathogen.
Study Design
Researchers investigated how adjuvants shape FimA B-cell epitope hierarchies and influence protective immunity in a murine model of acute pneumonia. BALB/c mice were intramuscularly immunized with recombinant FimA formulated in three clinically trialed adjuvants: AddaVax, AddaS03, and AlPO4. Following immunization, mice were challenged with lethal doses of the hvKP YBQ strain. The study assessed humoral anti-FimA responses, opsonophagocytic killing activities, inflammatory cytokine levels, and survival rates. ELISA-based linear B-cell epitope mapping was used to identify and characterize immunodominant FimA epitopes.
Results
Adjuvant choice significantly impacted the protective efficacy of the FimA vaccine. AddaS03-immunized mice exhibited 100% survival and markedly reduced pulmonary bacterial load following lethal hvKP challenge. In contrast, AddaVax-immunized mice showed only 40% survival. The FimA-immunized groups with different adjuvants also displayed varying opsonophagocytic killing activities and inflammatory cytokine levels, which likely contributed to the observed differences in protective immunity. ELISA mapping identified three novel immunodominant FimA epitopes, and their hierarchies were distinctly altered by the different adjuvants. A causal link was suggested between the FimA epitope hierarchy and protective efficacy in hvKP-infected mice. > Immunization with a mixture of these FimA immunodominant epitopes combined with AlPO4 achieved an 80% protection rate, and this combination also exerted a potent therapeutic effect when co-administered with low-dose meropenem.
Key Findings
- AddaS03-adjuvanted FimA vaccine achieved 100% survival and reduced bacterial load in hvKP-challenged mice.
- AddaVax-adjuvanted FimA vaccine resulted in only 40% survival in hvKP-challenged mice.
- Adjuvants significantly altered the hierarchy of immunodominant B-cell epitopes on FimA.
- A mixture of three novel FimA immunodominant epitopes plus AlPO4 provided 80% protection.
- The epitope mixture with AlPO4 showed potent therapeutic effects with low-dose meropenem.
Why It Matters
This research highlights the critical role of adjuvant selection in shaping the immune response to vaccine antigens like FimA, directly impacting protective efficacy against hvKP. For vaccine development, this means that simply identifying a promising antigen is insufficient; the choice of adjuvant is paramount for eliciting the most effective humoral immunity. Optimizing adjuvant choice is crucial for FimA vaccine efficacy against hvKP, potentially leading to a viable vaccine strategy. The finding that a specific epitope mixture combined with AlPO4 provided significant protection, even therapeutically with meropenem, suggests a pathway for developing multi-epitope vaccines that could offer both prophylactic and adjunctive therapeutic benefits against drug-resistant infections. This moves closer to a usable protocol by emphasizing rational adjuvant design.
klebsiella-pneumoniae
hvKP
vaccine
adjuvant
fimA
b-cell-epitope